Hepatitis
C Top News Articles
|
|
People
Who Naturally Clear Hepatitis
C Virus Have Lower Risk of Death than Chronic
Patients
8-31-2010
|
Pegylated
Interferon plus Ribavirin Has High Sustained
Response Rates in Children with Hepatitis C
8-31-2010
|
IL28B
Gene Pattern May Influence Susceptibility to
Hepatitis C Virus Genotypes
8-27-2010
|
Only
Fittest Hepatitis C Virus Strains Re-infect
New Liver after Transplantation
8-27-2010
|
Protease
Inhibitor TMC435 Shows Potent and Sustained
Efficacy for Genotype 1 Chronic Hepatitis C
8-24-2010
|
Silymarin
Milk Thistle Extract May Inhibit Hepatitis
C Virus Entry into Cells
8-20-2010
|
International
Study Links Tattoos with Higher
Risk of Hepatitis C
8-17-2010
|
HCV
Polymerase Inhibitor PSI-7977 Receives FDA
Fast Track Designation
8-17-2010
|
Addition
of HCV Protease Inhibitor Telaprevir
Can Shorten Interferon-based Hepatitis C Treatment
8-17-2010
|
HCV
Protease Inhibitor Boceprevir Increased Sustained
Response to
Interferon-based Therapy in Phase 3 Studies
8-06-2010
|
Hepatitis
C Virus Prevalence Has Decreased among U.S.
Blood Donors Since the Early 1990s
8-06-2010
|
Combination
Therapy with HCV Polymerase Inhibitor
ANA598 Produces 12-week Sustained Response
in Small Study
8-02-2010
|
Chronic
Hepatitis C Virus Infection Is Associated with Early Atherosclerosis
7-30-2010
|
Pharmasset
Starts New Phase 1b Clinical Trial of HCV
Polymerase Inhibitor PSI-938
7-30-2010
|
Hope
Against Hepatitis C
7-23-2010
|
Hepatitis
C Virus Can Remain Viable for Months in a Liquid
Environment at Low Temperatures
7-20-2010
|
Asian
Patients Respond as Well as Whites to Interferon-based
Therapy for Chronic Hepatitis C
7-13-2010
|
Response
at Week 8 Accurately Predicts Sustained Response to Pegylated
Interferon plus Ribavirin for Hepatitis C
7-13-2010
|
Eiger
HCV NS4B Inhibitor Exhibits Synergy with Experimental
HCV Protease Inhibitors
7-09-2010
|
Consensus
Interferon (Infergen) Label Changed to Include
Data on Dosing with Ribavirin
7-09-2010
|
Immune
Cells Show Signs of Senescence after Liver
Transplantation
7-09-2010
|
Chronic
Hepatitis C Linked to Increased Risk of Kidney
Cancer
7-06-2010
|
Sustained
Response to Antiviral Therapy Prevents Esophageal
Varices in Hepatitis C Patients with Cirrhosis
7-06-2010
|
FDA
Approves First Rapid Hepatitis
C Virus Antibody Blood Test
7-02-2010
|
Treating
Hepatitis C in People with Compensated
Cirrhosis Is Most Cost-effective Approach
7-02-2010
|
House
of Representatives Holds Hearing on the "Secret
Epidemic" of Viral Hepatitis
7-02-2010
|
Blood-boosting
Adjuvant Therapies Can Improve Response to
Interferon-based Treatment for Hepatitis C
6-25-2010
|
Human
Genome Sciences Announces FDA
Is Unlikely to Approve Albumin Interferon Once
Every 2 Weeks
6-22-2010
|
Physicians
Test for Hepatitis C
Based on Risk Factors but Should Expand Screening for
High-Prevalence Age Group
6-22-2010
|
Idenix
Begins Proof-of-Concept Study of HCV
Protease Inhibitor IDX320
6-18-2010
|
HCV
Rapidly Develops Resistance to Directing-acting
Agents, Indicating Need for Multidrug Combos
6-18-2010
|
Presidio
Pharmaceuticals Selects PPI-1301
as Second Hepatitis C Virus NS5A Inhibitor for Development
6-15-2010
|
CDC
Reports Increasing Incidence of Liver
Cancer, Mostly Due to Chronic Hepatitis B and
C
6-15-2010
|
Sex
Hormone Receptor May Explain Higher Risk of Hepatocellular
Carcinoma in Men
6-11-2010
|
Sustained
Virological Response at 12 Weeks Post-treatment May Be
as Good as 24 Weeks for Determining
Interferon Cure
6-11-2010
|
World
Hepatitis Alliance Releases Major
Report on Viral Hepatitis Policy at EASL Meeting
6-08-2010
|
75%
of Treatment-naive Genotype 1 Hepatitis C Patients Achieve
Sustained Response with Telaprevir
Combination, Most with 24 Weeks of Therapy
6-08-2010
|
ZymoGenetics
Begins Phase 2b Trial of Pegylated
Interferon Lambda
6-08-2010
|
San
Francisco HIV/HCV Coinfection
Community Forum on June 7
6-04-2010
|
HCV
Polymerase Inhibitor ANA598 Demonstrates 75%
Early Virological Response Rate in Phase 2 Trial
6-04-2010
|
HCV
Treatment May Be Less Effective in an Urban
Minority Population
6-04-2010
|
Nitazoxanide
Increases Response to Pegylated Interferon plus Ribavirin
in Treatment-naive and Non-responder Hepatitis
C Patients
5-28-2010
|
Rifaximin
Reduces Encephalopathy Recurrence, Improves Quality of
Life in People with Liver Cirrhosis
5-28-2010
|
Less
than Half of Drug Addiction Treatment Programs Screen
for Infectious Diseases such as HIV and Hepatitis
B or C
5-25-2010
|
People
Receiving Buprenorphine
instead of Methadone for Addiction Treatment Are More
Likely to Respond to Hepatitis
C Therapy
5-25-2010
|
Advocates
Rally in San Francisco and Washington to Raise Awareness
and Demand Funding for Hepatitis
B and C
5-21-2010
|
San
Francisco Senator Leland Yee Introduces Legislation to
Allow Pharmacies to Sell Non-prescription
Syringes
5-21-2010
|
Achillion
Announces Additional Promising Data from Phase
1b Trial of HCV Protease Inhibitor ACH-1625
5-21-2010
|
How
Well Do Needle Exchange Programs
Work?
5-21-2010
|
GlaxoSmithKline
Halts Study of Eltrombopag (Promacta)
in People with Liver Disease Due to Blood Clot Risk
5-18-2010
|
Controlled
Release Interferon (Locteron)
Every 2 Weeks Works as Well as Pegylated
Interferon but with Fewer Side Effects
5-18-2010
|
Vitamin
D Increases Sustained Response to Interferon-based
Therapy for Hepatitis C, May Improve Liver
Fibrosis
5-18-2010
|
May
19 is World Hepatitis Day, Raising Hepatitis
B and C Awareness
5-18-2010
|
GlaxoSmithKline
Halts Study of Eltrombopag (Promacta)
in People with Liver Disease Due to Blood Clot Risk
5-18-2010
|
Controlled
Release Interferon (Locteron)
Every 2 Weeks Works as Well as Pegylated Interferon but
with Fewer Side Effects
5-18-2010
|
Vitamin
D Increases Sustained Response to Interferon-based
Therapy for Hepatitis C, May Improve Liver
Fibrosis
5-14-2010
|
Many
Genotype 1 Hepatitis C Patients Can Be Cured with 24 Weeks
of Telaprevir plus Pegylated
Interferon/ribavirin
5-14-2010
|
Telaprevir
Monotherapy Is Potent against HCV Genotype
2 but Not 3; Best Results when Combined with Interferon/ribavirin
5-14-2010
|
Hepatitis
March on Washington, Rally in San Francisco
Set for May 19
5-11-2010
|
Combination
of 2 Nucleotide HCV Polymerase Inhibitors, PSI-7977
and PSI-938, Looks Good in Laboratory Study
5-11-2010
|
Measurable
Neurocognitive Impairment Signals Hepatic Encephalopathy
in People with Liver Cirrhosis
5-11-2010
|
Women
More Likely to Die while Awaiting Liver
Transplants under the MELD Allocation System
5-7-2010
|
PROTECT
Study Finds One-third of Liver
Transplant Patients Achieve Sustained Response
to Pegylated Interferon plus Ribavirin
5-7-2010
|
HCV
Polymerase Inhibitor IDX184,
Protease Inhibitor IDX320,
and Triple Combination Show Promising Antiviral Activity
5-4-2010
|
Experimental
HCV Polymerase Inhibitor RG7128 Is Effective
with Standard Therapy in Genotype 2/3 Patients
4-27-2010
|
HCV
Therapeutic Vaccine GI-5005 Improves Rate of
Sustained Response to Interferon-based Therapy for Hepatitis
C
4-27-2010
|
MARS
and Prometheus Artificial Liver Devices Offer
Some Benefits for Patients with Liver Failure, but Did
Not Improve Survival
4-27-2010
|
Closely
Individualized Treatment with Pegylated
Interferon plus Ribavirin Is Possible Based
on Baseline Viral Load and Early Response
4-23-2010
|
Gilead
Terminates Study of Caspase Inhibitor GS
9450 for Hepatitis C Due to Safety Concerns
4-23-2010
|
Experimental
HCV Protease Inhibitor BI 201335
Shows Robust Antiviral Activity in Genotype 1 Non-responders
4-23-2010
|
| |
HCV
Protease Inhibitor Danoprevir (RG7227/ITMN-191)
Shows Antiviral Activity at Lower Doses When Boosted
with Ritonavir
4-20-2010
|
HCV
Polymerase Inhibitor VX-222
Demonstrates Good Safety and Antiviral Activity in Treatment-naive
Genotype 1 Hepatitis C Patients
4-20-2010
|
EASL
International Liver Congress Presents
New Data on Hepatitis B and C Pathogenesis and Treatment
4-20-2010
|
Prior
Non-responders Achieve Treatment Success with Telaprevir
plus Pegylated Interferon and Ribavirin
4-20-2010
|
HCV
Protease Inhibitor Boceprevir
Demonstrates Durable Sustained Response with No Late Relapse
4-20-2010
|
HCV
Protease Inhibitor Telaprevir
plus Pegylated Interferon and Ribavirin Is
Effective in Genotype 1 Prior Non-responders
4-16-2010
|
FDA
Approves Rifaximin (Xifaxan) for Hepatic Encephalopathy
in People with Liver Disease
4-6-2010
|
Milk
Thistle Silibinin Extracts Inhibit HCV Polymerase
in Laboratory Study
4-6-2010
|
Investigational
HCV Inhibitor TMC435
Demonstrates Promising Safety and Efficacy in Phase 1
Study
4-2-2010
|
Novelos
Starts Phase 2 Trial of NOV-205
to Reduce Liver Damage in Non-responders to Interferon
Therapy for Hepatitis C
4-2-2010
|
African-Americans
and Hispanics Have Similar Poor Outcomes with Interferon-based
Therapy for Chronic Hepatitis C
4-2-2010
|
